Chemotherapy Clinical Trial
Official title:
Efficacy and Safety of Niraparib in Combination With Anlotinib Based on CA 125 Level in Newly Diagnosed Ovarian Cancer: A Open-label, Single Arm, Prospective Phase II Trial
This is a phase II trial to explore efficacy and safety of niraparib in combination with anlotinib based on CA 125 level in newly diagnosed ovarian cancer. After completion of 1st-line platinum-based chemotherapy with a normal CA-125 concentration, in patients with CA-125 increased > 35U/ml, and with no evidence of imaging recurrence, niraparib and anlotinib are used as 1st maintenance therapy for newly diagnosed advanced ovarian cancer after achieving complete or partial remission to platinum-containing chemotherapy. The primary objective of this study is to explore the efficacy of niraparib combined with anlotinib based on CA 125 level in newly diagnosed ovarian cancer with no evidence of imaging recurrence. A total o f36 patients will be enrolled in this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03652727 -
FX vs. ECG Guidance for PICC Insertion
|
N/A | |
| Not yet recruiting |
NCT05856656 -
Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer
|
N/A | |
| Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
| Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
| Recruiting |
NCT00797238 -
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC
|
N/A | |
| Not yet recruiting |
NCT05927857 -
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Completed |
NCT04466332 -
Comparison of Two ECG Guided PICC Insertion Techniques
|
N/A | |
| Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03701607 -
Effect of Chemotherapy on PD-L1 in NSCLC
|
||
| Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
| Recruiting |
NCT06208436 -
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
|
||
| Recruiting |
NCT05306301 -
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
|
Phase 2 | |
| Active, not recruiting |
NCT02304640 -
Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
|
||
| Completed |
NCT02298972 -
Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer
|
N/A | |
| Terminated |
NCT01249001 -
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
|
Phase 2 | |
| Recruiting |
NCT03089892 -
A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy
|
N/A | |
| Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04472403 -
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
|
||
| Terminated |
NCT02982694 -
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
|
Phase 2 |